Peptide Stacks, 503B and What the HHS Policy Does Not Cover

The HHS enforcement discretion policy published October 30, 2026 has been widely summarized as "peptides are back." The policy text is much narrower. HHS says it does not intend to take enforcement action only "when all of the following circumstances are present," and it lists ten.

Anything that misses one condition is outside the policy. This piece covers the most common gaps. For what the policy does cover, see our full explainer.

Combination products and "stacks"

Condition 7 says the compounded product "contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A." HHS gives its reason: a single ingredient makes it easier to attribute adverse events and outcomes to a specific substance, which it calls essential for safety surveillance.

So a preparation combining two listed peptides in one vial, such as BPC-157 with TB-500, is outside the policy. So is a listed peptide combined with any other active ingredient. Multi-peptide "stacks" sold as one product do not fit.

503B outsourcing facilities

The policy is titled for 503A compounding, and the compounders it names are a state-licensed pharmacy, a federal facility and a licensed physician. Outsourcing facilities registered under section 503B are not among them. Operators who buy from outsourcing facilities for other products should not assume the same supply route works for these six peptides.

Peptides that are not on the list

Appendix A lists exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Any other peptide is outside the policy.

That includes emideltide, also called delta sleep-inducing peptide (DSIP). It was the seventh peptide reviewed at FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026. FDA's briefing document concluded that the balance of criteria "weighs against" placing either emideltide form on the 503A bulks list, and found emideltide not well characterized. News reports said the committee did not back it; FDA has not posted meeting minutes we could find. Either way, emideltide is not in Appendix A.

Other peptides that are popular in wellness programs but not on the list are also outside the policy, whatever their regulatory history.

Office stock and batches ahead of prescriptions

Condition 10 requires compliance with section 503A's "patient specific prescription requirement." Products ordered for a clinic's shelf, to be assigned to patients later, do not rest on a patient-specific prescription and fall outside the policy. Neither does resale: the required label reads "This is a compounded drug product. Not for resale."

The policy does not separately address how much a pharmacy may prepare in anticipation of prescriptions. Do not build a program that depends on it.

Salt forms and routes not in Appendix B

Condition 2 ties each peptide to the identity and route limits in Appendix B:

• BPC-157: acetate only; subcutaneous, intramuscular, oral or topical.
• TB-500: acetate only; subcutaneous or intramuscular.
• Epitalon: acetate only; subcutaneous or intramuscular, in intermittent courses.
• MOTS-c: acetate only; subcutaneous or intramuscular.
• Semax: free base only; intranasal.
• KPV: acetate only; topical or oral.

Some examples of what falls outside: BPC-157 free base, Semax acetate, injectable KPV, intranasal BPC-157, and topical TB-500. FDA reviewed both salt forms of each peptide in July, but Appendix B covers only one form of each.

Two more limits apply to how a product is made and delivered. An oral product needs documentation that the formulation achieves adequate oral bioavailability in humans (condition 8). And the only device that may be co-packaged with or contain the product is an FDA 510(k)-cleared syringe (condition 9), so prefilled pens and other devices are outside.

Ingredients without a traceable source

Conditions 3 and 4 require bulk peptide from an FDA-registered original manufacturer that complies with CGMP, with a valid certificate of analysis that names the facility location. HHS says the policy is meant to discourage use of research-use-only peptides from foreign manufacturers. Material labeled "research use only," or without a qualifying COA, does not meet the policy.

States that do not allow it

The policy addresses federal enforcement. It does not change state law. A state board of pharmacy or medical board can still restrict or prohibit compounding, prescribing or dispensing of these peptides, and state positions may differ. Check each state before launch; our state compliance guides are a starting point.

The policy can change or end

The policy is non-binding and, in the words of the Federal Register notice, "does not establish any rights for any person." HHS says it may revisit the policy, in whole or in part, if a safety signal or product quality issue arises, "among other things." The notice also calls it a draft and invites comments through November 13, 2026.

Its natural end point is rulemaking. For each peptide, the policy lasts until that peptide is addressed in a final rule adding it to the 503A bulks list or not. A final rule that leaves a peptide off the list would end the discretion for that peptide.

Build programs that can stop a product quickly if the policy changes: know which patients receive which product, and have a plan for clinical follow-up.

What is still unsettled

• Whether HHS will revise the policy after the comment period, and when.
• How individual states will respond.
• How HHS will treat products just outside the conditions, such as a covered peptide in an unlisted form or route.
• Whether and when FDA will propose rules for any of the six peptides.

If you are planning a peptide program and want it built inside these limits from the start, tell us what you are building.

*This article is general information, not legal or medical advice.*